Savings Program

Pay as little as $30 cash or $20 commercial per month*

Print your prescription savings card now.

Click here to PRINT

3 steps to saving on the branded generic ROWEEPRA®

Ask your doctor to write ROWEEPRA® DAW on your prescription so you’ll receive the branded generic ROWEEPRA® at the pharmacy and pay as little as $30 for a 30-day supply, regardless of dosage. If your commercial insurance plan has ROWEEPRA® listed you could pay as little as $20 for a 30-day supply.

Present this printed Savings Card along with your prescription to the pharmacist and request the branded generic ROWEEPRA®. This card can be used up to 12 times per year.

When picking up your prescription, check the bag and the bottle label to confirm that you received the branded generic ROWEEPRA®.
To find a pharmacy in your area that carries Roweepra® or Roweepra® XR please visit:

*Program Restrictions: Not eligible if prescriptions are paid by any state or federally funded programs, including, but not limited to Medicare, Medicaid, VA, DOD, Tricare or Medigap. Void where prohibited by law. Not valid for a ROWEEPRA prescription reimbursed in full by any third-party payer. May not be combined with any other coupon, discount, savings card or other offer. Limited to one prescription per person for any 30-day period. The maximum benefit is $5 per 30-day prescription. No substitutions permitted. May not be accepted at all pharmacies.


This offer may be terminated, rescinded, revoked or amended by OWP Pharmaceuticals, Inc. at any
time, without notice

For general questions or inquiries please contact us at:
For Roweepra questions please contact us at:
To report safety related concerns please contact us at:

OWOS1040V2 05/18



ROWEEPRA is indicated for adjunctive therapy in the treatment of:


  • Partial onset seizures in patients one month of age and older with epilepsy
  • Myoclonic seizures in patients 12 years of age and older with juvenile myoclonic epilepsy
  • Primary generalized tonic-clonic seizures in patients 6 years of age and older with idiopathic generalized epilepsy





  • Behavioral abnormalities including psychotic symptoms, suicidal ideation, irritability, and aggressive behavior have been observed; monitor patients for psychiatric signs and symptoms
  • Suicidal Behavior and Ideation: Monitor patients for new or worsening depression, suicidal thoughts/behavior, and/or unusual changes in mood or behavior
  • Monitor for somnolence and fatigue and advise patients not to drive or operate machinery until they have gained sufficient experience on ROWEEPRA
  • Withdrawal Seizures: ROWEEPRA must be gradually withdrawn
  • Serious Dermatological Reactions including Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis
  • Coordination Difficulties
  • Hematological abnormalities; cases of agranulocytosis have been reported in the post-marketing setting
  • Increase in blood pressure; patients 1 month to
  • Seizure control during pregnancy: ROWEEPRA plasma levels may gradually decrease throughout pregnancy; monitor carefully patients during pregnancy and through the postpartum period




  • Psychiatric Symptoms
  • Suicidal Behavior and Ideation
  • Somnolence and Fatigue
  • Serious Dermatological Reactions
  • Coordination Difficulties
  • Hematologic Abnormalities
  • Increase in Blood Pressure


When used for partial onset seizures

In adult patients:

most common adverse reactions: asthenia, somnolence, headache, infection, dizziness


In pediatric patients:

most common adverse reactions: headache, nasopharyngitis, vomiting, somnolence, fatigue, aggression


In pediatric patients 1 month

most common adverse reactions: somnolence, irritability

When used for myoclonic seizures
Most common adverse reactions:

somnolence, neck pain, pharyngitis, depression


When used for primarily generalized tonic-clonic seizures
Most common adverse reactions: nasopharyngitis, fatigue, diarrhea


ROWEEPRA should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.


To provide information regarding the effects of in utero exposure to ROWEEPRA , physicians are advised to recommend that pregnant patients taking ROWEEPRA enroll in the North American Antiepileptic Drug (NAAED) pregnancy registry. This can be done by calling the toll free number 1-888-233-2334, and must be done by the patients themselves. Information on the registry can also be found at the website


Nursing mothers

ROWEEPRA is excreted in human milk. A decision whether discontinuing the drug or discontinuing nursing should be made.


Pediatric population
The safety and effectiveness of ROWEEPRA in the adjunctive treatment of partial onset seizures in pediatric patients age 1 month to 16 years old with epilepsy have been established.


The safety and effectiveness of ROWEEPRA as adjunctive treatment of myoclonic seizures in adolescents 12 years of age and older with juvenile myoclonic epilepsy have been established.


The safety and effectiveness of ROWEEPRA as adjunctive therapy in the treatment of primary generalized tonic-clonic seizures in pediatric patients 6 years of age and older with idiopathic generalized epilepsy have been established.


Geriatric patients
No overall differences in safety were observed between these subjects and younger subjects.


Renal impairment
Clearance of ROWEEPRA is decreased in patients with renal impairment and is correlated with creatinine clearance.



You are now leaving the website